Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2026Nature Cardiovascular Research

ALPK3 gene addition to restore sarcomeric quality control

View Full Paper
Ask AI
Bookmark
Share

Key result

ALPK3 gene therapy reverses cardiomyopathy in mice and restores contractile function in human cardiac organoids.

Why the study?

Loss-of-function variants of ALPK3 cause severe forms of cardiomyopathy with no curative treatment.

Does ALPK3 gene addition restore contractile function and reverse disease in preclinical models of ALPK3 and TTN-truncation cardiomyopathy?

Population

Mice, human cardiac organoids, and an organoid model of TTN-truncation cardiomyopathy

Comparison

Therapy delivering full-length ALPK3

Design

Preclinical animal and organoid study

Authors

JGJulian GrünewaldMassachusetts General HospitalCKChristian KupattGerman Centre for Cardiovascular Research

Discussion

Loading...

Member takes

Implication

ALPK3 gene therapy merits human trials in genetic cardiomyopathy; leaves open translation from mice and organoids to patients.

Key Points

  • To determine whether gene addition of full-length ALPK3 can restore sarcomeric quality control and rescue heart contractile function in genetic cardiomyopathy models.
  • Administered full-length ALPK3 gene delivery therapy in mice harboring loss-of-function ALPK3 mutations.
  • Evaluated contractile performance and phenotypic rescue in human cardiac organoids with ALPK3 deficiency and TTN-truncation cardiomyopathy models.
  • Full-length ALPK3 gene addition prevented disease onset and reversed established cardiomyopathy in mice.
  • ALPK3 delivery restored contractile function in human cardiac organoids and rescued contraction defects in an organoid model of TTN-truncation cardiomyopathy.

Structured PICO

Does ALPK3 gene addition restore contractile function and reverse disease in preclinical models of ALPK3 and TTN-truncation cardiomyopathy?

P
Population
Mice with ALPK3 loss-of-function cardiomyopathy, human cardiac organoids, and an organoid model of TTN-truncation cardiomyopathy
I
Intervention
Therapy delivering full-length ALPK3 (gene addition)
O
Outcome
Prevention and reversal of disease in mice, restoration of contractile function in human cardiac organoids, and rescue of impaired contraction in TTN-truncation organoid modelsurrogate

ALPK3 gene addition shows promise as a therapeutic strategy for severe cardiomyopathies caused by ALPK3 loss-of-function or TTN-truncation variants in preclinical models.

Cite This Study

Grünewald et al. (2026) studied this question. Gene therapy delivering full-length ALPK3 prevents and reverses cardiomyopathy in mice and restores contractile function in human cardiac organoids, including TTN-truncation models.

synapsesocial.com/papers/6a969c56535111e2d4ce8d23https://doi.org/10.1038/s44161-026-00867-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiomyopathy in α-Kinase 3 (ALPK3)–Deficient Mice2011 · 49 citations
  2. 2Untying the knot: protein quality control in inherited cardiomyopathies2018 · 19 citations
  3. 3Alpha protein kinase 3 gene therapy restores heart function in mouse and human models of cardiomyopathy2026 · 1 citations
  4. 4Cardiotropic AAV gene therapy for heart failure: a phase 1 trial2025 · 28 citations
  5. 5ALPK3-deficient cardiomyocytes generated from patient-derived induced pluripotent stem cells and mutant human embryonic stem cells display abnormal calcium handling and establish that ALPK3 deficiency underlies familial cardiomyopathy2016 · 69 citations